-
Revisiting the “Gut-Liver-Brain Axis” through the Lens of Bile Acids – Key Advances and Prospects in Basic and Clinical Research
AASLD Roundtable Discussion: Revisiting the “Gut-Liver-Brain Axis” through the Lens of Bile Acids – Key Advances and Prospects in Basic and Clinical Research Editor’s Note: The recently concluded AASLD 2023,…
-
AASLD Interview | Dr.Fengmin Lu: Exploring Interferon Cure Advantages in Chronic Hepatitis B, Delving into Mechanisms to Guide New Drug Development
Editor’s Note: At the just-concluded Annual Summit of Hepatology, the American Association for the Study of Liver Diseases (AASLD2023), Professor Fengmin Lu’s team from Peking University presented three contributions (1…
-
AASLD Exclusive Interview | Professor Monica Tincopa: Four New Insights into the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
Editor’s Note: At the recently concluded international annual grand event in the field of hepatology – the American Association for the Study of Liver Diseases Annual Meeting (AASLD 2023), Professor…
-
WCLC Live | Dr. Johnson: ADC Targeting B7-H3 Demonstrates Effective and Durable Response in Refractory SCLC Patients
The 2023 World Conference on Lung Cancer (WCLC), organized by the International Association for the Study of Lung Cancer (IASLC), took place in Singapore from September 9-12. Dr. Melissa L. Johnson from Northwestern University’s Feinberg School of Medicine presented pivotal findings on antibody-drug conjugates (ADC) for treating small cell lung cancer (SCLC). We had the…
-
Dr. Wu Yilong, Dr. Cheng Ying, and Dr.Han Baohui Discuss the latest advancements in Small Cell Lung Cancer Research and Analyze the Development of ADC
For the first time in three years, Chinese experts were able to participated in the WCLC conference in person, following the end of the impact of the COVID-19 pandemic , engaging in face-to-face discussions with international scholars. Dr. Wu Yilong, Dr. Cheng Ying, and Dr. Han Baohui shared their experiences of attending the conference in…
-
ESMO Highlights | Professor Wei Yu’s Commentary on Advances in Neoadjuvant Therapy and Bladder Preservation in Bladder Cancer
Editor’s Note: Bladder cancer is a common tumor in the urinary system, with muscle-invasive bladder cancer (MIBC) accounting for approximately 20% of all bladder cancers. Nearly half of non-muscle-invasive bladder…
-
ESMO in Five Minutes | Prof. Haitao Zhao : Highlights of Advances in the Treatment of Cholangiocarcinoma
95MO: Efficacy of Tinengotinib in Treating Advanced Fibroblast Growth Factor Receptor (FGFR) Inhibitor Resistant/Recurrent Cholangiocarcinoma Patients Background Fibroblast Growth Factor Receptor inhibitors (FGFRi) have been shown to play a role…
-
ESMO 2023丨Professor Zhimin Shao: monarcE Study 5-Year Follow-Up Data Revealed, Sustained Benefit for Patients
Editor’s Note: The monarchE study is a randomized, open-label, multicenter Phase III clinical trial designed to compare the efficacy and safety of abemaciclib combined with endocrine therapy versus endocrine therapy…
Connecting Medical Expertise through Media